• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Scheiner Zachary

    3/25/24 8:38:44 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $GRPH alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Scheiner Zachary

    (Last) (First) (Middle)
    C/O RA CAPITAL MANAGEMENT
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/21/2024
    3. Issuer Name and Ticker or Trading Symbol
    LENZ Therapeutics, Inc. [ LENZ ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    No securities are beneficially owned.
    /s/ Zachary Scheiner 03/25/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GRPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRPH

    DatePrice TargetRatingAnalyst
    2/23/2023$3.00 → $2.00Neutral → Underperform
    BofA Securities
    2/23/2023$3.00Overweight → Neutral
    Cantor Fitzgerald
    2/23/2023Outperform → Market Perform
    Cowen
    1/25/2023Buy → Neutral
    BTIG Research
    1/18/2023$7.00 → $3.00Buy → Neutral
    BofA Securities
    1/6/2023$11.00 → $2.00Outperform → Mkt Perform
    SVB Leerink
    1/6/2023$14.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    9/15/2022$12.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $GRPH
    SEC Filings

    View All

    SEC Form 424B3 filed by Graphite Bio Inc.

    424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/9/24 4:18:06 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Graphite Bio Inc.

    10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/8/24 5:11:18 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/8/24 4:05:56 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    $GRPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

    Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

    3/8/24 5:00:00 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    LENZ Therapeutics and Graphite Bio Announce Merger Agreement

    - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

    11/15/23 7:00:00 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

    Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

    10/30/23 7:00:00 AM ET
    $GRPH
    $PEAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $GRPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/14/24 5:29:43 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/25/24 8:48:33 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    $GRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/14/24 5:29:43 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

    3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/28/24 4:31:03 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/25/24 8:48:33 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    $GRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Graphite Bio downgraded by BofA Securities with a new price target

    BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously

    2/23/23 8:58:13 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Graphite Bio downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00

    2/23/23 8:56:04 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Graphite Bio downgraded by Cowen

    Cowen downgraded Graphite Bio from Outperform to Market Perform

    2/23/23 6:14:16 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    $GRPH
    Financials

    Live finance-specific insights

    View All

    Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

    Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

    3/8/24 5:00:00 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    LENZ Therapeutics and Graphite Bio Announce Merger Agreement

    - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

    11/15/23 7:00:00 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

    Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

    10/30/23 7:00:00 AM ET
    $GRPH
    $PEAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $GRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

    SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    4/8/24 2:46:09 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Graphite Bio Inc.

    SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

    3/28/24 4:30:24 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Graphite Bio Inc.

    SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

    3/28/24 4:16:06 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    $GRPH
    Leadership Updates

    Live Leadership Updates

    View All

    Graphite Bio Appoints Alethia Young as Chief Financial Officer

    Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e

    3/2/22 8:00:00 AM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care